247 related articles for article (PubMed ID: 36951584)
1. Prognostic value of esophageal cancer immune prognostic index in advanced esophageal squamous cell carcinoma patients with anti-programmed cell death-1 therapy.
Lu J; Du L; Lei X; Zhang Z
Cancer Med; 2023 May; 12(10):11334-11343. PubMed ID: 36951584
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma.
Li Y; Wang K; Zhao E; Li B; Li S; Dong X; Yuan L; Yang H
Pathol Oncol Res; 2022; 28():1610245. PubMed ID: 35721326
[No Abstract] [Full Text] [Related]
3. Prognostic and predictive impact of neutrophil-to-lymphocyte ratio and HLA-I genotyping in advanced esophageal squamous cell carcinoma patients receiving immune checkpoint inhibitor monotherapy.
Wang L; Zhu Y; Zhang B; Wang X; Mo H; Jiao Y; Xu J; Huang J
Thorac Cancer; 2022 Jun; 13(11):1631-1641. PubMed ID: 35437954
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of inflammatory markers and clinical features for survival in advanced or metastatic esophageal squamous cell carcinoma patients receiving anti-programmed death 1 treatment.
Da L; Qu Z; Zhang C; Shen Y; Huang W; Zhang Y; Gu K
Front Oncol; 2023; 13():1144875. PubMed ID: 37035159
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Unresectable or Metastatic Esophageal Cancer Patients With Anti-PD-1 Therapy.
Gao Y; Zhang Z; Li Y; Chen S; Lu J; Wu L; Ma Z; Hu Y; Zhang G
Front Oncol; 2022; 12():834564. PubMed ID: 35494073
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors.
Guo JC; Lin CC; Lin CY; Hsieh MS; Kuo HY; Lien MY; Shao YY; Huang TC; Hsu CH
Anticancer Res; 2019 Oct; 39(10):5675-5682. PubMed ID: 31570466
[TBL] [Abstract][Full Text] [Related]
7. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis.
Zhu X; Shanzhou Q; Li D; Pang X; Ma D
BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782
[TBL] [Abstract][Full Text] [Related]
8. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
[No Abstract] [Full Text] [Related]
9. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
[TBL] [Abstract][Full Text] [Related]
10. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
Lu Y; Wang W; Wang F
Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.
Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y
Front Oncol; 2021; 11():697865. PubMed ID: 34692478
[TBL] [Abstract][Full Text] [Related]
12. Preoperative systemic inflammation score (SIS) is superior to neutrophil to lymphocyte ratio (NLR) as a predicting indicator in patients with esophageal squamous cell carcinoma.
Fu X; Li T; Dai Y; Li J
BMC Cancer; 2019 Jul; 19(1):721. PubMed ID: 31331297
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
14. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study.
Gao L; Tang L; Peng J; Hu Z; Yang J; Liu B
Front Immunol; 2024; 15():1353445. PubMed ID: 38576619
[TBL] [Abstract][Full Text] [Related]
15. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
Qi WX; Wang X; Li C; Li S; Li H; Xu F; Chen J; Zhao S; Li H
Thorac Cancer; 2023 Jun; 14(17):1556-1566. PubMed ID: 37089116
[TBL] [Abstract][Full Text] [Related]
16. [Study on the prognostic influencing factors of esophageal squamous cell carcinoma and the predictive value of inflammatory reaction indexes on its postoperative recurrence].
Wang X; Wang Z; Lu WL; Zhao GF
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):160-164. PubMed ID: 36781237
[No Abstract] [Full Text] [Related]
17. Nomogram Based on Monocyte-to-Lymphocyte Ratio to Predict Survival of Unresectable Esophageal Squamous Cell Carcinoma Who Receive First-Line PD-1/PD-L1 Inhibitors Combined with Chemotherapy.
Ma X; Ding Y; Qian J; Wan M; Li N; Mao C; Xiao C; Jiang H; Zheng Y; Wu L; Chen X; Xu N
Curr Oncol; 2022 Nov; 29(11):8937-8954. PubMed ID: 36421355
[TBL] [Abstract][Full Text] [Related]
18. Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy.
Chen W; Li D; Bian X; Wu Y; Xu M; Wu M; Tao M
Nutr Cancer; 2023; 75(1):207-218. PubMed ID: 36190755
[No Abstract] [Full Text] [Related]
19. PD-1 inhibitor monotherapy versus combination therapy: A real-world study of patients with recurrent or metastatic advanced esophageal squamous cell carcinoma after first-line chemotherapy.
Yang G; Sun H; Zhou C; Sun N; Xu L; Huang W; Li B
J Cancer Res Ther; 2022 Apr; 18(2):545-552. PubMed ID: 35645126
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer.
Booka E; Kikuchi H; Haneda R; Soneda W; Kawata S; Murakami T; Matsumoto T; Hiramatsu Y; Takeuchi H
Anticancer Res; 2022 Jun; 42(6):2977-2987. PubMed ID: 35641297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
